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InterleukinIncreasing evidence indicates that caspase recruitment domain (CARD)-mediated caspase-1 (CASP1)
assembly is an essential process for its activation and subsequent interleukin (IL)-1b release, leading
to the initiation of inﬂammation. Both CARD16 and CARD17 were previously reported as inhibitory
homologs of CASP1; however, their molecular function remains unclear. Here, we identiﬁed that
oligomerization activity allows CARD16 to function as a CASP1 activator. We investigated the molec-
ular characteristics of CARD16 and CARD17 in transiently transfected HeLa cells. Although both
CARD16 and CARD17 interacted with CASP1CARD, only CARD16 formed a homo-oligomer.
Oligomerized CARD16 formed a ﬁlament-like structure with CASP1CARD and a speck with
apoptosis-associated speck-like protein containing a CARD. A ﬁlament-like structure formed by
CARD16 promoted CASP1 ﬁlament assembly and IL-1b release. In contrast, CARD17 did not form a
homo-oligomer or ﬁlaments and inhibited CASP1-dependent IL-1b release. Mutated CARD16D27G,
mimicking the CARD17 amino acid sequence, formed a homo-oligomer but failed to form a
ﬁlament-like structure. Consequently, CARD16D27G weakly promoted CASP1 ﬁlament assembly and
subsequent IL-1b release. These results suggest that oligomerized CARD16 promotes CARD-mediated
molecular assembly and CASP1 activation.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Activation of caspase-1 (CASP1) and subsequent processing of
interleukin (IL)-1b are essential for initiation of the inﬂammatory
response. In this process, large molecular complexes, known as
the inﬂammasomes, serve as platforms for CASP1 activation [1,2].
Several types of inﬂammasomes have been reported and typicallycontain one of the NLR family proteins, apoptosis-associated
speck-like protein containing a caspase recruitment domain
(ASC), and cysteine protease CASP1. Among the inﬂammasomes,
the NLRP3 inﬂammasome is the most extensively studied; it recog-
nizes danger signals and induces the sterile inﬂammatory response
in various diseases. NLRP3 is composed of C-terminal leucine-rich
repeats (LRRs), a central nucleotide domain termed the NACHT
domain, and an N-terminal effector domain [pyrin domain (PYD)]
[2]. ASC contains an N-terminal PYD and a C-terminal caspase
recruitment domain (CARD) [3]. CASP1 consists of a CARD and cat-
alytic domains (p10 and p20) [4,5]. Notably, each inﬂammasome
component possesses oligomerization activity. NLRP3 homo-
oligomerizes via its NACHT domain when stimulated by danger
signals and the NLRP3 PYD homotypically interacts with that of
ASC after which CARD of ASC recruits and binds to CASP1. These
interactions ﬁnally assemble the NLRP3 inﬂammasome, leading
to the formation of the active CASP1 tetramer, which processes
pro-IL-1b into its biologically active mature form. Interestingly,
both PYD and CARD of ASC were originally identiﬁed as the
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Although their physiological relevance remains unclear, a recent
investigation revealed that both PYD and CARD of ASC and CASP1
form ﬁlaments and that the endogenous NLRP3 inﬂammasome
forms a large ﬁlamentous complex [6].
NLRP3 inﬂammasomes are activated by various endogenous
danger signals such as extracellular adenosine triphosphate (ATP),
monosodium urate, and cholesterol crystals and induce IL-1b
release and subsequent inﬂammatory responses that contribute
to disease development [7–9]. We previously demonstrated the
importance of the NLRP3 inﬂammasome in the pathophysiology
of myocardial ischemia–reperfusion, vascular injury, abdominal
aneurysm, and chronic kidney disease [10–13]. Furthermore, recent
clinical studies have demonstrated the therapeutic effects of block-
ing IL-1 in several types of sterile inﬂammatory diseases [14,15].
Several CARD-only proteins (COPs) are CASP1 CARD homologs.
Of these, previous investigations suggested that CARD16 (also
known as pseudo-ICE), CARD17 (also known as INCA), and
CARD18 (also known as Iceberg) can function as negative regula-
tors of CASP1 activity by binding the CARD of CASP1 [16–19]. All
of these COPs are located on chromosome 11q22.3 and share
highly conserved amino acid sequences with CASP1 [20]. CARD16
consists of 97 amino acids and shows 92% amino acid identity with
the CARD of CASP1. CARD17 also shares 81% sequence identity
with the CARD of CASP1. In contrast, CARD18 is less similar to
CASP1 than CARD16 and has 53% identity with the CARD of
CASP1. These COPs are not present in the rodent genome but are
present in the human genome, suggestive of the complexity of
CASP1 regulation in humans. Although the CARD interaction is
essential for the inﬂammasome assembly, the functional difference
among these COPs remains unclear. In the present study, we inves-
tigated the molecular characteristics of CARD16 and CARD17 with
respect to the recruitment and activation of CASP1.2. Materials and methods
2.1. Plasmids
The polymerase chain reaction (PCR)-generated cDNAs encod-
ing human CARD16, CARD17, CASP1, CASP1CARD (1–102), ASC,
ASCPYD (1–100), and ASCCARD (101–195) were subcloned into
the N-terminal 3  Flag-tagged pCDNA3.1 vector or N-terminal
Myc-tagged pMG2 vector. Enzymatically inactive CASP1C285A,
mutated CARD16D27G, and mutated CARD16R45C were generated
using the PrimeSTAR Mutagenesis Basal kit (Takara Bio, Shiga,
Japan).
2.2. In silico analysis of promoter region
The promoter region of human CASP1 (2000 base pairs
upstream of the initiation codon) was compared with that of
CARD16, CARD17, and CARD18 using a BLAST algorithm (http://
blast.ncbi.nlm.nih.gov).
2.3. Isolation of human PBMCs and cell culture
HEK-293T and HeLa cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (Wako, Osaka, Japan) supplemented with 10% fetal
calf serum (FCS) and antibiotics. THP-1 cells, HL60 cells, and
human PBMCs were cultured in RPMI1640 (Sigma, St Louis, MO,
USA) supplemented with 10% FCS and antibiotics. PBMCs were iso-
lated from ﬁve healthy male volunteers (25–40 years old) with
Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK). This study
protocol was approved by the ethical committee of Jichi Medical
University and all subjects provided written informed consent.THP-1 macrophages were differentiated with 200 nM PMA for
24 h. Transfection was performed using Lipofectamine 2000 (Life
Technologies, Grand Island, NY, USA) according to manufacturer’s
protocol or PEI MAX (Polysciences, Warrington, PA, USA) as
described previously [21].
2.4. Reverse transcription and real-time PCR
Total RNA was prepared using the ISOGEN system (Nippon
Gene Co., Tokyo, Japan) according to the manufacturer’s instruc-
tions. Total RNA was reverse transcribed using a Super Script
VILO cDNA Synthesis kit (Life Technologies). Real-time PCR
were performed using SYBR Premix Ex Taq II (Takara Bio). The
primers used in the assay were as follows: CASP1 (forward,
50-GAAGCTCAAAGGATATGGAAACAAA-30; reverse, 50-AAGACGTG-
TGCGGCTTGACT-30), CARD16 (forward, 50-TGCTCCCCTTGCATA-
AAGGA-30; reverse, 50-CCAGTTTGCAACTCTTTACCTAAACC-30),
CARD17 (forward, 50 CTTCCTTCCTAGGTTCAACTTTCATT-30,
Reverse; 50-GTGCTGGGCATCTGTGCTT-30), CARD18 (forward,
50–AAGATGGGTTTGCACTAAGAGAGAA-30; reverse, 50- TGGAAGA-
AGCTCTGGGAAGTCT-30), and ACTB (forward, 50- GGCACTCTTCC
AGCCTTCCTTC-30; reverse, 50-GCGGATGTCCACGTCACACTTCA-30).
A dilution series of the pCR2.1 plasmid encoding the target
sequence was used as the standard for absolute quantiﬁcation.
2.5. IL-1b measurement
The IL-1b level was measured by enzyme-linked immunosor-
bent assay (ELISA) using a commercial kit (R&D Systems,
Minneapolis, MN, USA). The supernatants were precipitated with
ice-cold acetone and resolved in 1  Laemmli buffer for western
blot analysis.
2.6. In vitro protein interaction assays
HeLa cells in 12-well culture plates were transfected with
1.6 lg of the indicated plasmids for the co-immunoprecipitation
assay. After 24 h, they were lysed in Nonidet P (NP)-40 buffer
(10 mM Tris–HCl, pH 7.4, 150 mM NaCl, and 1% NP-40) supple-
mented with a protease inhibitor cocktail (Sigma). After centrifu-
gation, the supernatants were subjected to immunoprecipitation,
and the precipitated proteins were analyzed as the insoluble frac-
tion. The supernatants were immunoprecipitated using speciﬁc
antibodies in combination with protein G or protein A-Sepharose
(GE Healthcare). HeLa cells were lysed in cross-linking buffer
(20 mM phosphate buffer, pH 8.0, 150 mM NaCl, and 1% NP-40)
for the cross-linking assay. After centrifugation, the supernatants
were placed on ice with 2 mM bis(sulfosccinimidyl)suberate
(BS3) for 2 h, and the crosslinking reaction was terminated by add-
ing an excess of glycine.
2.7. Western blot analysis
Samples were separated by SDS–PAGE and transferred to PVDF
membranes. After blocking with Tris-buffered saline containing 2%
casein, the membranes were incubated with the following primary
antibodies: anti-b actin monoclonal antibody (Ab) (clone AC-15;
Sigma), anti-Flag monoclonal Ab (clone M2; Sigma), anti-IL-1b
polyclonal Ab (H153; Santa Cruz Biotechnology, Dallas, TX, USA),
anti-Myc polyclonal Ab (MBL, Nagoya, Japan).
2.8. Immunocyotochemistry
Cells were cultured in 8-well slide glass chambers and ﬁxed
with 10% neutral buffered formalin for 10 min at room tempera-
ture, and then permeabilized with PBS containing 0.1% Triton
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min, the slides were incubated with primary antibodies for 1 h.
The following antibodies were used: anti-human ASC polyclonal
Ab (Enzo Life Sciences), anti-Flag M2 monoclonal Ab (Sigma), and
anti-Myc polyclonal Ab (MBL). Unbound antibodies were washed
with PBS and the slides were incubated with the following sec-
ondary antibodies: Alexa Fluor 488 donkey anti-rabbit IgG, Alexa
Fluor 488 goat anti-mouse IgG, Alexa Fluor 594 donkey anti-rabbit
IgG, and Alexa Fluor 594 goat anti-mouse IgG (Life Technologies).
Nuclei were co-stained with Hoechst33342 and ﬂuorescence was
detected using confocal laser scanning microscopy (Fv10i,
Olympus).
2.9. Statistical analysis
Data are expressed as mean ± standard error. Differences
between multiple group means were determined by one-way anal-
ysis of variance (ANOVA) combined with the Turkey–Kramer test.
All analyses were performed using the Stat Plus, ver. 2009
(Analyst Soft). A p-value of <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. CARD16 and CARD17 expression in human hematopoietic cells
We ﬁrst compared the CASP1 and COPs promoter regions and
found that the CASP1 promoter regions are conserved within
CARD16 and CARD17 but not within CARD18. In silico analyses
showed that CASP1 and CARD16 or CARD17 promoter regions
share 83.8% or 80.2% sequences homology in the 1314 bp or
1334 bp upstream of the initiation codon, respectively. The
CASP1 and COP expression proﬁles were analyzed to investigate
the most abundantly expressed COPs in human hematopoietic
cells. Although both CARD16 and CARD17 possessed similar pro-
moter regions, only CARD16 exhibited comparable expression
levels to CASP1 in PBMCs (Fig. 1). The CARD17 and CARD18 expres-
sion levels were considerably lower than that of CARD16 in other
human hematopoietic cell lines such as HL-60 and THP-1. In partic-
ular, CARD18 expression was not detectable in HL-60 cells.
3.2. CARD16 forms high-molecular weight complexes with CASP1CARD
Homo-oligomerization of CARD is required for CASP1 activa-
tion. Thus, we next compared the molecular characteristics of
CARD16 and CARD17. We examined their oligomerization activity10-7 
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Fig. 1. Expression of CARD16 and CARD17 in human hematopoietic cells. Absolute
quantiﬁcation of COP expression in PBMCs, THP-1 monocytes, PMA-differentiated
THP-1 macrophages, HL-60 cells, and PMA-differentiated HL-60 cells. The relative
copy number of each gene was calculated using a plasmid encoding their target
sequence. Data are mean ± standard error. N.D. indicates that no gene expression
was not detected.in HeLa cells, which have lower expression levels of these genes
than hematopoietic cells. We transfected plasmids containing the
CARD domains of CASP1 (CASP1CARD), CARD16, and CARD17 into
HeLa cells, and analyzed their activity using a cross-linking assay.
As expected, the formation of the CASP1CARD oligomer was clearly
detected (Fig. 2A). Similarly, CARD16 oligomerization was
apparently detected, whereas CARD17 did not form any oligomers.
We subsequently transfected Flag-tagged and Myc-tagged
CASP1CARD, CARD16 or CARD17 to conﬁrm whether a homomeric
interaction was responsible for the formation of the oligomer and
conducted a co-immunoprecipitation assay. Both CASP1CARD and
CARD16 were co-immunoprecipitated by their homo-interactions,
but Myc-tagged CARD17 was not co-immunoprecipitated by Flag-
tagged CARD17 (Fig. 2B). We assessed intracellular localization to
address how these homomeric complexes are formed in cells.
Interestingly, both CASP1CARD and CARD16 formed ﬁlament-like
structures (Fig. 2C). Besides the homomeric interaction, the inter-
action between FlagCASP1CARD and MycCARD16 or MycCARD17
was assessed by co-immunoprecipitation assay. Substantial quan-
tities of MycCASP1CARD and MycCARD16 were co-immunoprecip-
itated with FlagCASP1CARD, whereas MycCARD17 was weakly
co-immunoprecipitated with FlagCASP1CARD (Fig. 2D). In contrast,
a similar quantity of FlagCASP1CARD was detected in each co-im-
munoprecipitated fraction when the immunoprecipitation was
performed using anti-Myc antibody (Fig. 2E). The quantities of
immunoprecipitated proteins likely reﬂected the degree of poly-
merization; that is, polymerized CARD16 was co-immunoprecipi-
tated with CASP1CARD, but homo-oligomerization defective
CARD17 was less precipitated. In accordance with the co-immuno-
precipitation results, CARD16 formed a ﬁlament-like structure that
co-localized with ﬁlaments of CASP1CARD (Fig. 2F). In contrast,
CARD17 abrogated CASP1CARD ﬁlament formation suggesting that
the inhibitory effect of CARD17 on CASP1 activation is mediated by
inhibiting its homo-oligomerization.3.3. CARD16 interacts with ASC and localizes in ASC speck aggregates
Since ASC also contains CARD, we assessed the interaction
between CARD16 and ASCCARD. As reported previously [22], ASC
forms insoluble high-molecular weight complexes through poly-
merization, even in the presence of detergents when expressed
transiently (Fig. 3A). In addition, CASP1CARD and CARD16 were
also detected in the insoluble fraction probably because of its poly-
merization activity. Therefore, we constructed a plasmid encoding
only PYD of ASC (ASCPYD) or CARD of ASC (ASCCARD) to avoid the
formation of insoluble complexes. A co-immunoprecipitation
assay in transfected HeLa cells revealed that ASCCARD interacted
with CARD16 but not with CARD17 (Fig. 3B and C). In contrast,
ASCPYD did not interact with CARD16 or CARD17.
Immunocytochemistry showed co-localization of CARD16 in
ASC-speck (Fig. 3D). CARD16 formed a ﬁlament-like structure that
co-localized with ASCARD ﬁlaments but not with that of ASCPYD
(Fig. 3E and F). Therefore, it was likely that the localization of
CARD16 in ASC-speck was mediated through co-polymerizing with
ASCCARD. In support of these results, Western blot analysis
showed that both CARD16 and ASC were detected in the insoluble
fraction (Fig. 3A). Conversely, CARD17 failed to co-localize with
ASC-speck (Fig. 3D).3.4. CARD16 promotes assembly of CASP1 ﬁlaments
CARD16 interacts with CASP1CARD and forms a ﬁlament-like
structure. Thus, we hypothesized that CARD16 promotes CASP1
assembly. To test this hypothesis, CASP1C285A, a mutant
deﬁcient in protease activity, was used to avoid the induction of
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Fig. 2. CARD16 forms high-molecular weight complexes with CASP1CARD. HeLa cells were transiently transfected with plasmids encoding FlagCASP1CARD, FlagCARD16, and
FlagCARD17. (A) Cell lysates were cross-linked with BS3, then separated by SDS–PAGE and visualized by Western blot. (B) HeLa cells were transiently transfected with
plasmids encoding FlagCASP1CARD together with MycCASP1CARD, FlagCARD16 together with MycCARD16, or FlagCARD17 together with MycCARD17. Cell lysates were
immunoprecipitated with anti-Flag antibody and detected by Western blot analysis. (C) HeLa cells were transiently transfected with plasmids encoding FlagCASP1CARD,
FlagCARD16, or FlagCARD17. Cells were immunostained with anti-Flag antibody. (D and E) The interactions between CASP1CARD and CARD-containing proteins were
detected by co-immunoprecipitation. HeLa cells were transiently transfected with FlagCASP1CARD together with MycCASP1CARD, MycCARD16, or MycCARD17. Cell lysates
were immunoprecipitated with (D) anti-Flag antibody or (E) anti Myc antibody and detected byWestern blot analysis. (F) Co-localization of CASP1CARD and CARD-containing
proteins was analyzed by immunocytochemistry. Transfected Hela cells were immunostained with anti-Flag and anti-Myc antibodies.
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immunocytochemistry in transiently transfected HeLa cells.
CASP1C285A was dispersed throughout the cells when it was
expressed alone (Fig. 4A). Notably, CASP1C285A formed a ﬁlament-
like structure that co-localized with CARD16 but not with
CARD17 when it was co-transfected with CARD16 or CARD17
(Fig. 4A). Supporting this result, Western blot analysis revealedthat both CASP1C285A and CARD16 were detected in the insoluble
fraction (Fig. 4B). These results suggest that CARD16 promotes
CASP1 ﬁlament assembly. CASP1, CARD16, and IL-1b were co-ex-
pressed in HeLa cells to assess whether the assembled CASP1 and
CARD16 complex is functional. Indeed, co-expression of CARD16
enhanced CASP-1-mediated IL-1b release, whereas CARD17
reduced it (Fig. 4C). Notably, a similar change in CASP1-dependent
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352 T. Karasawa et al. / FEBS Open Bio 5 (2015) 348–356mature IL-1b release was detected in supernatants by Western blot
analysis (Fig. 4D, 1.6-fold change in CARD16 co-expressing cells
and 0.76-fold change in CARD17 co-expressing cells).
Furthermore, we investigated whether CARD16 or CARD17 affects
the interaction between CASP1 and ASC. As expected, CASP1C285A
co-localized with ASC-speck when CASP1C285A was co-expressed
with ASC (Fig. 4E). The co-expression of CARD16 retainedCASP1C285A in ASC-speck. In contrast, the co-expression of
CARD17 reduced CASP1C285A localized in the ASC-speck and
increased dispersed CASP1C285A. In fact, CARD17 reduced the for-
mation of insoluble CASP1C285A when it was co-expressed with
ASC (Fig. 4F). These results suggest that CARD16 could participate
in the formation of ASC-speck with CASP1C285A, whereas CARD17
prevents CASP1 co-localization with ASC speck.
AS
C
 +
Fl
ag
C
AS
P1
C
28
5A
A
Fl
ag
C
AS
P1
C
28
5A
DAPI
anti-Myc
(Alexa594)
anti-Flag
(Alexa488)Merge
C
B
D
MycCASP1C285A
MycCARD16
MycCARD17
FlagASC
− −− +− −
− +− −− −
− + ++ +−
Insoluble
Insoluble
Insoluble
MycCASP1C285A
β-actin
MycCASP1C285A
+ +−+− +
FlagASC
MycCASP1C285A
MycCARD16
MycCARD17
− − + +− +
− − +−− +
− − −++ −
MycCARD17
MycCARD16
MycCASP1C285A
β-actin
MycCASP1C285A
Insoluble
Insoluble
Soluble
Soluble
Soluble
Soluble
Soluble
Soluble
Soluble
MycCARD17
MycCARD16
FlagASC
MycCARD17
MycCARD16
MycCARD17
MycCARD16
anti-Flag
(Alexa594) DAPIMerge
anti-ASC
(Alexa488)
m
oc
k
C
AR
D
16
C
AR
D
17
m
oc
k
M
yc
C
AR
D
17
M
yc
C
AR
D
16
− − + +− +
− − +−− +
− − −++ −
− − + +− +
− − +−− +
− − −++ −
β-actin
pro-IL-1β
pro-IL-1β
mature IL-1β
Supernatant
FlagCASP1
FlagCARD16
FlagCARD17
IL1B
− − + +− + + ++− − −
Lysate
Lysate
Lysate
FlagCASP1
FlagCARD16
FlagCARD17
0 
100 
200 
300 
400 
500 
− − + +− +
− − +−− +
− − −++ −
− − + +− +
− − +−− +
− − −++ −
FlagCASP1
FlagCARD16
FlagCARD17
IL1B − − + +− + + ++− − −
IL
-1
β (
pg
/m
L)
E F
*
*
20 μm
20 μm
Fig. 4. CARD16 recruits CASP1 to its ﬁlament-like structure. (A) Assembly of CASP1C285A was analyzed by immunocytochemistry. HeLa cells were transiently transfected with
FlagCASP1C285A together with MycCARD16 or MycCARD17. After 24 h, the cells were immunostained with anti-Flag and anti-Myc antibodies. (B) Formation of the insoluble
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354 T. Karasawa et al. / FEBS Open Bio 5 (2015) 348–3563.5. Filament formation is required for CARD16-induced CASP1
ﬁlament assembly
We attempted to generate a CARD16 mutant that did not form a
ﬁlament to investigate whether the formation of the CARD16 ﬁla-
ment is required for CARD16-induced CASP1 assembly. We gener-
ated two CARD16 mutants mimicking CARD17 using alignment
analysis (Fig. 5A). Amino acids Asp-27 and Arg-45 are critical for
the interaction between CASP1 and other CARD-containing pro-
teins [23]. Immunocytochemistry revealed that no ﬁlaments
formed in CARD16D27G-expressing HeLa cells, whereas they were
formed weakly in CARD16R45C-expressing cells (Fig. 5B).
However, CARD16D27G preserved its homo-oligomerization activity
(Fig. 5C). CARD16D27G was not co-localized with the CASP1CARD
ﬁlament-like structure (Fig. 6A), although CARD16D27G interacted
with CASP1CARD (Fig. 6B). We transfected CARD16, CARD16D27G,
and CARD16R45C into HeLa cells and examined their localization
by immunocytochemistry to determine whether CARD16D27G lacks
the ability to assemble CASP1. As expected, CARD16D27G failed to
induce ﬁlamentous CASP1 assembly (Fig. 6C). In support of this
result, the formation of insoluble CASP1C285A was prevented when
it was co-expressed with CARD16D27G (Fig. 6D). Finally, we exam-
ined whether CARD16 mutants enhance CASP1-dependent IL-1b
release and conﬁrmed that both CARD16D27G and CARD16R45C
weakly promoted IL-1b release compared to CARD16 (Fig. 6E
and F).
4. Discussion
In the present study, we found that CARD16 and CARD17, but
not CARD18, have a conserved promoter region with CASP1. The
CARD16 expression level was comparable to that of CASP1. In con-
trast, the CARD17 and CARD18 expression levels were considerably
lower than that of CASP1. Molecular characteristics analyses
revealed that CARD16 demonstrated potent oligomerization activ-
ity, whereas CARD17 failed to form a homo-oligomer. CARD16
clearly formed a large ﬁlament-like structure, indicating a highlypolymerized molecular complex. CARD16 promoted a ﬁlamentous
assembly of CASP1C285A, which lacks autocatalytic activity.
Moreover CARD16 enhanced CASP1-dependent IL-1b release.
Furthermore, the CARD16 mutants with attenuated oligomeriza-
tion activity weakly promoted IL-1b release. These results indicate
that CARD16 and CARD17 have different roles in CARD-mediated
molecular assembly and CASP1 activation and provide new
insights into the molecular mechanism underlying the regulation
of the inﬂammasomes.
Although COPs are reportedly CASP1 inhibitors, the most abun-
dant COPs in human hematopoietic cells have not been deter-
mined. We determined that CARD16 and CARD17 shared a
similar promoter region with CASP1, but no homology was
detected in the CARD18 promoter region. In addition, a comparison
of their expression levels revealed that CARD16 was the most
abundant COP in hematopoietic cells. The CARD17 and CARD18
expression levels were considerably lower than that of CASP1.
Therefore, we assumed that CARD16 may contribute to regulating
CASP1 in hematopoietic cells.
We clariﬁed two functional differences between CARD16 and
CARD17: an interaction with ASC and oligomerization activity.
Previous studies reported the interaction between CARD16 or
CARD17 and CASP1. However, their interaction with ASC remains
to be determined. We clearly showed that CARD16 interacts with
ASC via CARD–CARD interactions and co-localizes with ASC-speck.
Although the precise role of CARD16 in ASC-speck was not eluci-
dated in this study, CARD16 could not prevent CASP1 co-localiza-
tion with ASC-speck. Another remarkable difference between
CARD16 and CARD17 is their oligomerization activity. Cross-link-
ing and immunocytochemical analyses revealed that CARD16 not
only formed an oligomer but also formed large ﬁlament-like struc-
tures with CASP1. One study demonstrated that both PYD and
CARD in the inﬂammasomes can form ﬁlaments [6]. Activated
NLRP3 nucleates the PYD ﬁlaments of ASC, which cluster
ASCCARD. The clustered ASCCARD causes the ﬁlamentous assem-
bly of CASP1. By analogy, we postulated that CARD16-mediated ﬁl-
ament formation is critical for CASP1 ﬁlament assembly. In support
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form ﬁlaments, assembled CASP1 ﬁlaments less effectively com-
pared with that of CARD16. The signiﬁcance of CARD-mediated ﬁl-
ament formation has been investigated in other CARD-containing
proteins. For example, Qiao et al. [24] recently reported that the ﬁl-
ament formation by B-cell lymphoma/leukemia 10 (Bcl10), CARD-
membrane-associated guanylate kinase 1(CARMA1), and Malt1 is
necessary to form the CARMA1 signalosome, which induces
nuclear factor kappa beta (NF-jB) activation [24,25]. Since
CARD16 interacts with Bcl10 [18], it may be possible that the ﬁla-
ment formed by CARD16 is also involved in other inﬂammatory
processes. Unlike CARD16, CARD17 inhibited both ﬁlamentous
assembly and ASC-mediated assembly of CASP1. The reason for
the distinct functions of CARD16 and CARD17 may depend on
the lower homology between CASP1 and CARD17. The defective
homo-oligomerization activity may permit CARD17 to inhibit
CASP1. Although there is no direct evidence, it is plausible that
CARD17 abrogates the ﬁlamentous assembly of CASP1 by termi-
nating polymerization.
Previous investigations suggested that COPs such as CARD16,
CARD17, and CARD18 act as endogenous inhibitors of CASP1 acti-
vation [16–19]. However, we found that CARD16 clearly promoted
CASP1 ﬁlament assembly and subsequent IL-1b release. Although
the reason for the discrepancy between previous studies and our
study is currently unclear, it could be based on differences in
experimental conditions. In previous reports, lipopolysaccharide
(LPS) was used to induce IL-1b release, and the IL-1b levels were
measured only by ELISA, which detects both pro-IL-1b and mature
IL-1b [17–19]. Therefore, the effects of COPs on IL-1b processing
were not determined. As LPS up-regulates IL-1b at the transcrip-
tional level, it cannot be ruled out that CARD16 may be involved
in transcriptional regulation of IL-1b. In addition, CARD16 is also
involved in RIP2-mediated NF-jB induction [17–19]. Further
investigations are needed to clarify the role of CARD16 in tran-
scriptional and post-transcriptional regulation of IL-1b.
In conclusion, functional differences between CARD16 and
CARD17 may be explained by their oligomerization activity;
CARD16 assists with CASP1 assembly, resulting in CASP1 activation
and subsequent IL-1b release. However, several limitations should
be noted. First, because CARD16 and CARD17 are present in
humans, but not in rodents, loss-of-function studies are limited.
Second, because the molecular characteristics of COPs were mainly
analyzed in HeLa cells, the exact role of endogenous CARD16 in
hematopoietic cells remains unclear. Further studies are needed
to clarify the precise roles of CARD16 and CARD17 in physiological
and/or pathological inﬂammatory processes.
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